scispace - formally typeset
Z

Zhen Zhang

Researcher at Johns Hopkins University

Publications -  224
Citations -  16297

Zhen Zhang is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 57, co-authored 189 publications receiving 13444 citations. Previous affiliations of Zhen Zhang include Medical University of South Carolina & Children's National Medical Center.

Papers
More filters
Journal ArticleDOI

KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring

TL;DR: The acquired biologically plausible results provide new insights into network rewiring as a mechanistic principle and illustrate the performance of KDDN on various simulations and real gene expression datasets, and further compare the results with those obtained by the most relevant peer methods.
Patent

Biomarkers for breast cancer

TL;DR: In this paper, protein-based biomarkers and biomarker combinations were used to classify a subject sample as breast cancer or non-breast cancer, and the biomarkers can be detected by SELDI mass spectrometry.
Posted Content

OmicsMapNet: Transforming omics data to take advantage of Deep Convolutional Neural Network for discovery.

TL;DR: OmicsMapNet approach to take advantage of existing deep leaning frameworks to analyze high-dimensional omics data as 2-dimensional images to capture the functional hierarchical structure of genes in 2D images.
Journal ArticleDOI

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer

TL;DR: The pac litaxel plus fluorouracil regimen did not show overall survival superiority over paclitaxel regimens with cisplatin or carboplatin in patients with locally advanced esophageal squamous cell carcinoma who are in chemoradiation therapy.
Journal ArticleDOI

Urinary glycoproteins associated with aggressive prostate cancer.

TL;DR: Glyopeptides of urinary glycoproteins associated with aggressive prostate cancer are identified using a quantitative mass spectrometry-based glycoproteinomic approach and demonstrated their potential to serve as noninvasive urinary Glycoprotein biomarkers worthy of further validation by a multi-center study.